메뉴 건너뛰기




Volumn 63, Issue 8, 2011, Pages 863-868

Newly approved drugs for Alzheimer disease: Effectiveness and limitation

Author keywords

Alzheimer disease; Cholinesterase inhibitor; N methyl D aspartic acid (NMDA) receptor antagonist; Symptomatic benefits

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE;

EID: 80052074393     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (36)
  • 1
    • 61849185913 scopus 로고    scopus 로고
    • Recent developments in Alzheimer's disease therapeutics
    • Rafii MS, Aisen PS: Recent developments in Alzheimer's disease therapeutics. BMC Med 7: 7, 2009
    • (2009) BMC Med , vol.7 , pp. 7
    • Rafii, M.S.1    Aisen, P.S.2
  • 2
    • 77951776829 scopus 로고    scopus 로고
    • Alzheimer's disease: Strategies for disease modification
    • Citron M: Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398, 2010
    • (2010) Nat Rev Drug Discov , vol.9 , pp. 387-398
    • Citron, M.1
  • 3
    • 77953778864 scopus 로고    scopus 로고
    • Treatment of Alzheimer's disease: Symptomatic and disease-modifying approaches
    • Galimberti D, Scarpini E: Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. Curr Aging Sci 3: 46-56, 2010
    • (2010) Curr Aging Sci , vol.3 , pp. 46-56
    • Galimberti, D.1    Scarpini, E.2
  • 4
    • 0011162190 scopus 로고
    • Selective loss of central cholinergic neurons in Alzheimer's disease
    • Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1976 (Pubitemid 8004505)
    • (1976) Lancet , vol.2 , Issue.8000 , pp. 1403
    • Davies, P.1    Maloney, A.J.F.2
  • 5
    • 0019410162 scopus 로고
    • Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
    • DOI 10.1002/ana.410100203
    • Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10: 122-126, 1981 (Pubitemid 11053099)
    • (1981) Annals of Neurology , vol.10 , Issue.2 , pp. 122-126
    • Whitehouse, P.J.1    Price, D.L.2    Clark, A.W.3
  • 6
    • 0024576043 scopus 로고
    • The pontomesecephalotegmental cholinergic system does not degenerate in Alzheimer's disease
    • Woolf NJ, Jacobs RW, Butcher LL: The pontomesecephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci Lett 96: 277-282, 1989
    • (1989) Neurosci Lett , vol.96 , pp. 277-282
    • Woolf, N.J.1    Jacobs, R.W.2    Butcher, L.L.3
  • 7
    • 0024315598 scopus 로고
    • Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon
    • DOI 10.1016/0306-4522(89)90360-6
    • Woolf NJ, Gould E, Butcher LL: Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience 30: 143-152, 1989 (Pubitemid 19159803)
    • (1989) Neuroscience , vol.30 , Issue.1 , pp. 143-152
    • Woolf, N.J.1    Gould, E.2    Butcher, L.L.3
  • 8
    • 0025110182 scopus 로고
    • β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
    • DOI 10.1016/0006-8993(90)91355-K
    • Koh JY, Yang LL, Cotman CW: β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315-320, 1990 (Pubitemid 20377714)
    • (1990) Brain Research , vol.533 , Issue.2 , pp. 315-320
    • Koh, J.-Y.1    Yang, L.L.2    Cotman, C.W.3
  • 9
    • 0027973241 scopus 로고
    • Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
    • Mesulam MM, Geula C: Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36: 722-727, 1994
    • (1994) Ann Neurol , vol.36 , pp. 722-727
    • Mesulam, M.M.1    Geula, C.2
  • 10
    • 0027337833 scopus 로고
    • Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
    • Wright CI, Geula C, Mesulam MM: Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 34: 373-384, 1993 (Pubitemid 23259607)
    • (1993) Annals of Neurology , vol.34 , Issue.3 , pp. 373-384
    • Wright, C.I.1    Geula, C.2    Mesulam, M.-M.3
  • 11
    • 34547211420 scopus 로고    scopus 로고
    • Galanthamine, a natural product for the treatment of Alzheimer's disease
    • Marco L, do Carmo Carreiras M: Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent Pat CNS Drug Discov 1: 105-111, 2006
    • (2006) Recent Pat CNS Drug Discov , vol.1 , pp. 105-111
    • Marco, L.1    Do Carmo Carreiras, M.2
  • 12
    • 0034732104 scopus 로고    scopus 로고
    • Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
    • DOI 10.1016/S0014-2999(00)00093-5, PII S0014299900000935
    • Maelicke A, Albuquerque EX: Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393: 165-170, 2000 (Pubitemid 30193413)
    • (2000) European Journal of Pharmacology , vol.393 , Issue.1-3 , pp. 165-170
    • Maelicke, A.1    Albuquerque, E.X.2
  • 15
    • 78650057569 scopus 로고    scopus 로고
    • Galantamine-induced amyloid- {β} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors
    • Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, et al: Galantamine-induced amyloid- {β} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285: 40180-40191, 2010
    • (2010) J Biol Chem , vol.285 , pp. 40180-40191
    • Takata, K.1    Kitamura, Y.2    Saeki, M.3    Terada, M.4    Kagitani, S.5
  • 16
    • 38449088916 scopus 로고    scopus 로고
    • Rivastigmine in the treatment of Alzheimer's disease: An update
    • Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2: 17-32, 2007
    • (2007) Clin Interv Aging , vol.2 , pp. 17-32
    • Onor, M.L.1    Trevisiol, M.2    Aguglia, E.3
  • 17
    • 64149090366 scopus 로고    scopus 로고
    • Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review
    • Kurz A, Farlow M, Lefevre G: Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 63: 799-805, 2009
    • (2009) Int J Clin Pract , vol.63 , pp. 799-805
    • Kurz, A.1    Farlow, M.2    Lefevre, G.3
  • 18
    • 13844251864 scopus 로고    scopus 로고
    • Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease
    • Venneri A, McGeown WJ, Shanks MF: Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16: 107-110, 2005
    • (2005) Neuroreport , vol.16 , pp. 107-110
    • Venneri, A.1    McGeown, W.J.2    Shanks, M.F.3
  • 19
    • 75149131084 scopus 로고    scopus 로고
    • A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease
    • Bailey JA, Lahiri DK: A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112: 843-853, 2010
    • (2010) J Neurochem , vol.112 , pp. 843-853
    • Bailey, J.A.1    Lahiri, D.K.2
  • 20
    • 53149137393 scopus 로고    scopus 로고
    • Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine
    • Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, et al: Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203: 12-22, 2008
    • (2008) J Neuroimmunol , vol.203 , pp. 12-22
    • Nizri, E.1    Irony-Tur-Sinai, M.2    Faranesh, N.3    Lavon, I.4    Lavi, E.5
  • 21
    • 68849109872 scopus 로고    scopus 로고
    • Progression from mild cognitive impairment to Alzheimer's disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
    • Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R: Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics 19: 635-646, 2009
    • (2009) Pharmacogenet Genomics , vol.19 , pp. 635-646
    • Ferris, S.1    Nordberg, A.2    Soininen, H.3    Darreh-Shori, T.4    Lane, R.5
  • 22
    • 0032892343 scopus 로고    scopus 로고
    • Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
    • DOI 10.1016/S0028-3908(99)00019-2, PII S0028390899000192
    • Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38: 735-767, 1999 (Pubitemid 29187336)
    • (1999) Neuropharmacology , vol.38 , Issue.6 , pp. 735-767
    • Parsons, C.G.1    Danysz, W.2    Quack, G.3
  • 23
    • 77950350271 scopus 로고    scopus 로고
    • Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias
    • Thomas SJ, Grossberg GT: Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4: 367-377, 2009
    • (2009) Clin Interv Aging , vol.4 , pp. 367-377
    • Thomas, S.J.1    Grossberg, G.T.2
  • 25
    • 56749091391 scopus 로고    scopus 로고
    • Longitudinal multimodal imaging in mild to moderate Alzheimer disease: A pilot study with memantine
    • Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, et al: Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 79: 1312-1317, 2008
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , pp. 1312-1317
    • Schmidt, R.1    Ropele, S.2    Pendl, B.3    Ofner, P.4    Enzinger, C.5
  • 26
    • 34748915821 scopus 로고    scopus 로고
    • Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease
    • DOI 10.1159/000107099
    • Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L: Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 24: 247-252, 2007 (Pubitemid 47482070)
    • (2007) Dementia and Geriatric Cognitive Disorders , vol.24 , Issue.4 , pp. 247-252
    • Degerman, G.M.1    Kilander, L.2    Basun, H.3    Lannfelt, L.4
  • 27
    • 57049085109 scopus 로고    scopus 로고
    • Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging
    • Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, et al: Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86: 2784-2791, 2008
    • (2008) J Neurosci Res , vol.86 , pp. 2784-2791
    • Scholtzova, H.1    Wadghiri, Y.Z.2    Douadi, M.3    Sigurdsson, E.M.4    Li, Y.S.5
  • 28
    • 74149089703 scopus 로고    scopus 로고
    • Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid β (Aβ) peptide in the human neuroblastoma cells
    • Ray B, Banerjee PK, Greig NH, Lahiri DK: Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid β (Aβ) peptide in the human neuroblastoma cells. Neurosci Lett 470: 1-5, 2010
    • (2010) Neurosci Lett , vol.470 , pp. 1-5
    • Ray, B.1    Banerjee, P.K.2    Greig, N.H.3    Lahiri, D.K.4
  • 29
    • 42149142899 scopus 로고    scopus 로고
    • Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial
    • DOI 10.2174/156720508783884576
    • Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83-89, 2008 (Pubitemid 351536358)
    • (2008) Current Alzheimer Research , vol.5 , Issue.1 , pp. 83-89
    • Porsteinsson, A.P.1    Grossberg, G.T.2    Mintzer, J.3    Olin, J.T.4
  • 30
    • 66149095869 scopus 로고    scopus 로고
    • Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
    • Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, et al: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 600-607, 2009
    • (2009) J Neurol Neurosurg Psychiatry , vol.80 , pp. 600-607
    • Lopez, O.L.1    Becker, J.T.2    Wahed, A.S.3    Saxton, J.4    Sweet, R.A.5
  • 31
    • 21544467552 scopus 로고    scopus 로고
    • Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials
    • Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331: 321-327, 2005
    • (2005) BMJ , vol.331 , pp. 321-327
    • Kaduszkiewicz, H.1    Zimmermann, T.2    Beck-Bornholdt, H.P.3    Van Den Bussche, H.4
  • 32
    • 33644658662 scopus 로고    scopus 로고
    • The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
    • Loveman E, Green C, Kirby J, Takeda A, Picot J, et al: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 10: iii-iv, ix-xi, 1-160, 2006
    • (2006) Health Technol Assess , vol.10
    • Loveman, E.1    Green, C.2    Kirby, J.3    Takeda, A.4    Picot, J.5
  • 33
    • 36849078870 scopus 로고    scopus 로고
    • Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials
    • Raschetti R, Albanese E, Vanacore N, Maggini M: Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4: e338, 2007
    • (2007) PLoS Med , vol.4
    • Raschetti, R.1    Albanese, E.2    Vanacore, N.3    Maggini, M.4
  • 34
    • 60749130048 scopus 로고    scopus 로고
    • Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis
    • Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, et al: Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. Clin Interv Aging 3: 719-728, 2008
    • (2008) Clin Interv Aging , vol.3 , pp. 719-728
    • Campbell, N.1    Ayub, A.2    Boustani, M.A.3    Fox, C.4    Farlow, M.5
  • 35
    • 47849119964 scopus 로고    scopus 로고
    • Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis
    • Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, et al: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211-225, 2008 (Pubitemid 352037861)
    • (2008) Clinical Interventions in Aging , vol.3 , Issue.2 , pp. 211-225
    • Hansen, R.A.1    Gartlehner, G.2    Webb, A.P.3    Morgan, L.C.4    Moore, C.G.5    Jonas, D.E.6
  • 36
    • 70350517148 scopus 로고    scopus 로고
    • Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine
    • Rodda J, Morgan S, Walker Z: Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21: 813-824, 2009
    • (2009) Int Psychogeriatr , vol.21 , pp. 813-824
    • Rodda, J.1    Morgan, S.2    Walker, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.